| Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer RL Coleman, GF Fleming, MF Brady, EM Swisher, KD Steffensen, ... New England Journal of Medicine 381 (25), 2403-2415, 2019 | 768 | 2019 |
| Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology DK Armstrong, RD Alvarez, JN Bakkum-Gamez, L Barroilhet, K Behbakht, ... Journal of the National Comprehensive Cancer Network 19 (2), 191-226, 2021 | 469 | 2021 |
| Ovarian cancer, version 1.2016, NCCN clinical practice guidelines in oncology RJ Morgan, DK Armstrong, RD Alvarez, JN Bakkum-Gamez, K Behbakht, ... Journal of the National Comprehensive Cancer Network 14 (9), 1134-1163, 2016 | 323 | 2016 |
| NCCN guidelines insights: Ovarian cancer, version 1.2019: Featured updates to the NCCN guidelines DK Armstrong, RD Alvarez, JN Bakkum-Gamez, L Barroilhet, K Behbakht, ... Journal of the National Comprehensive Cancer Network 17 (8), 896-909, 2019 | 235 | 2019 |
| Pertuzumab, trastuzumab, and standard anthracycline-and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE … SM Swain, MS Ewer, G Viale, S Delaloge, JM Ferrero, M Verrill, ... Annals of oncology 29 (3), 646-653, 2018 | 219 | 2018 |
| Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial MR Mirza, EÅ Lundqvist, MJ Birrer, RP Christensen, GB Nyvang, ... The Lancet Oncology 20 (10), 1409-1419, 2019 | 217 | 2019 |
| Ovarian cancer, version 2.2013 RJ Morgan, RD Alvarez, DK Armstrong, RA Burger, L Chen, L Copeland, ... Journal of the National Comprehensive Cancer Network 11 (10), 1199-1209, 2013 | 155 | 2013 |
| Combating subclonal evolution of resistant cancer phenotypes SW Brady, JA McQuerry, Y Qiao, SR Piccolo, G Shrestha, DF Jenkins, ... Nature communications 8 (1), 1231, 2017 | 147 | 2017 |
| NCCN guidelines® insights: Ovarian cancer, version 3.2022: Featured updates to the NCCN guidelines DK Armstrong, RD Alvarez, FJ Backes, JN Bakkum-Gamez, L Barroilhet, ... Journal of the National Comprehensive Cancer Network 20 (9), 972-980, 2022 | 139 | 2022 |
| Epithelial ovarian cancer RJ Morgan, RD Alvarez, DK Armstrong, B Boston, RA Burger, L Chen, ... Journal of the National Comprehensive Cancer Network 9 (1), 82-113, 2011 | 134 | 2011 |
| First-in-human phase I study of GSK2126458, an oral pan-class I phosphatidylinositol-3-kinase inhibitor, in patients with advanced solid tumor malignancies P Munster, R Aggarwal, D Hong, JHM Schellens, R Van Der Noll, ... Clinical Cancer Research 22 (8), 1932-1939, 2016 | 97 | 2016 |
| Ovarian cancer, version 3.2012 RJ Morgan, RD Alvarez, DK Armstrong, RA Burger, M Castells, L Chen, ... Journal of the National Comprehensive Cancer Network 10 (11), 1339-1349, 2012 | 92 | 2012 |
| Too many women are dying from cervix cancer: Problems and solutions DK Gaffney, M Hashibe, D Kepka, KA Maurer, TL Werner Gynecologic oncology 151 (3), 547-554, 2018 | 88 | 2018 |
| Adenocarcinoma of the cervix: should we treat it differently? NL Williams, TL Werner, EA Jarboe, DK Gaffney Current oncology reports 17, 1-10, 2015 | 83 | 2015 |
| Management of cancer‐associated thrombotic microangiopathy: What is the right approach? TL Werner, N Agarwal, HM Carney, GM Rodgers American journal of hematology 82 (4), 295-298, 2007 | 82 | 2007 |
| Endometrial cancers harboring mutated fibroblast growth factor receptor 2 protein are successfully treated with a new small tyrosine kinase inhibitor in an orthotopic mouse model S Taurin, CH Yang, M Reyes, S Cho, DM Coombs, EA Jarboe, TL Werner, ... International Journal of Gynecologic Cancer 28 (1), 2018 | 79 | 2018 |
| Recurrent early stage endometrial cancer: Patterns of recurrence and results of salvage therapy SR Francis, BJ Ager, OA Do, YHJ Huang, AP Soisson, MK Dodson, ... Gynecologic oncology 154 (1), 38-44, 2019 | 77 | 2019 |
| Significant evidence for a heritable contribution to cancer predisposition: a review of cancer familiality by site F Albright, C Teerlink, TL Werner, LA Cannon-Albright BMC cancer 12, 1-7, 2012 | 69 | 2012 |
| State of the science in cervical cancer: where we are today and where we need to go DS Dizon, HJ Mackay, GM Thomas, TL Werner, EC Kohn, D Hess, ... Cancer 120 (15), 2282-2288, 2014 | 60 | 2014 |
| Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors AW Tolcher, R Kurzrock, V Valero, R Gonzalez, RS Heist, AR Tan, ... Cancer chemotherapy and pharmacology 85, 673-683, 2020 | 46 | 2020 |
